Monopar Therapeutics Inc. (MNPR), an emerging biopharmaceutical company that specializes in children oncology and is manufacturing exclusive therapeutics produced to increase life expectancy and enhance the standard of life for people effected with cancer. MNPR has reported that Monopar’s Urokinase plasminogen activator (uPA) antibody fragment radiotracer, is predicted to point out breast cancers using PET imaging while treatment.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Urokinase plasminogen activator (uPA) is an accepted biomarker and is used to choose adequate drug treatment for breast cancer patients in accordance to clinical study regulations. uPA and its receptor uPARcollectively eradicate aggressive tumors which lead to cancer at other parts and eventually death. After publishing a peer-review study which had a positive response from the medical community around the globe, shares of the company rose by 16%.
Monopar Forms An Alliance serial medtech entrepreneur to Explore development options for MNPR-101
MNPR has recently stated a contractual agreement with seasoned Med-tech executive, Andrew Cittadine, to form strategic options for MNPR-101 as a uPAR imaging agent in various types of cancer. The entrepreneur is a veteran in the healthcare industry NS has a history of building startups from concept through acquisition, including successful exits of Sensant Corp, where he was vice president of marketing. His latest credentials include being the chief executive officer for Diagnostics Photonics, which specializes in cancer imaging.
“Mr. Cittadine’s extensive experience in the oncology diagnostics and surgical imaging space combined with his previous successes makes for an ideal collaboration on exploring the potential of MNPR-101,” stated by Andrew Mazar, PhD, Chief Scientific Officer attomolar. Hence Mrcittadine has proven to be significant for MNPR growth with investors taking a keen interest.
A strategic alliance with seasoned med-tech executives has shown to be extremely significant in increasing the Monopar Therapeutics Inc (NASDAQ: MNPR), valuation with the company being keen on producing results.